The optimal hemoglobin in dialysis patients - A critical review

Seminars in Dialysis

Volumn 21, Issue 1, 2008, Pages 1-6

  Singh, Ajay K ^a   Fishbane, Steven ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PRACTICE GUIDELINE; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

ANEMIA; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 38749085650     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00329.x     Document Type: Review

References (44)

1. Fried W : Hematological complications of chronic renal failure. Med Clin North Am 62 : 1363 1379, 1978
2. United States Renal Data System : Annual Data Report. 2006
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D CHOIR Investigators : Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 : 2085 2098, 2006
4. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A CREATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071 2084, 2006
5. Tonelli M, Owen WF Jr., Jindal K, Winkelmayer WC, Manns B : Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 66 : 1712, 2004 author reply 1712 1713
6. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure : National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 (4 Suppl. 3 S192 S240, 1997
7. IV. NKF-K/DOQI. Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 37 (1 Suppl. 1 S182 S238, 2001
8. KDOQI; National Kidney Foundation. II : Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 47 (5 Suppl. 3 S16 S85, 2006
9. U.S. Food and Drug Administration Information for Healthcare, Center for Drug Evaluation and Research. Public Health Advisory. Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm
10. Lowrie EG, Lew NL : Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol 12 : 276 283, 1992
11. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W : Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12 : 2465 2473, 2001
12. Collins AJ, Ma JZ, Ebben J : Impact of hematocrit on morbidity and mortality. Semin Nephrol 20 : 345 349, 2000
13. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K : Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 : 1181 1191, 2006
14. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI : Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68 : 2323 2330, 2005
15. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ : Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 : 121 132, 2004
16. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N : Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl 87 : S6 S11, 2003
17. Krieger N, Lowy I, Aronowitz R, Bigby J, Dickersin K, Garner E, Gaudilliere JP, Hinestrosa C, Hubbard R, Johnson PA, Missmer SA, Norsigian J, Pearson C, Rosenberg CE, Rosenberg L, Rosenkrantz BG, Seaman B, Sonnenschein C, Soto AM, Thornton J, Weisz G : Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 59 : 740 748, 2005
18. Phrommintikul A, Haas SJ, Elsik M, Klum H : Mortality and target haemoglobin concentrations in anemia patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 : 381 388, 2007
19. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584 590, 1998
20. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D : Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 : 2180 2189, 2005
21. Levin A : Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 22 : 309 312, 2007
22. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW, Shadur CA, Benz RL, Teehan BP, Revicki DA, Sarokhan BJ, Abels RI : Effects of recombinant human erythropoietin on renal function in chronic renal failure. Am J Kidney Dis 24 : 777 784, 1994
23. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O : Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 : 176 185, 1997
24. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK : Beneficial influence of recombinant erythropoietin on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 : 307 312, 2001
25. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC : Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66 : 753 760, 2004
26. Garcia DL, Anderson S, Rennke HG, Brenner BM : Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 85 : 6142 6146, 1988
27. Lafferty HM, Garcia DL, Rennke HG, Troy JL, Anderson S, Brenner BM : Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol 1 : 1180 1185, 1991
28. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D CHOIR Investigators : Anemia of CKD: the CHOIR Study Revisited. Nephrol Dial Transplant, 2007 [Epub ahead of print]
29. Strippoli GF, Tognoni S, Navaneethan SD, Nicolucci A, Craig JC : Haemoglobin targets: we were wrong, time to move on. Lancet 369 : 346 350, 2007
30. Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC POWER Study Group : Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61 : 392 405, 2004
31. Provenzano R, Bhaduri S, Singh AK PROMPT Study Group : Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease; the PROMPT study : Clin Nephrol 64 : 113 123, 2005
32. Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT : Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 22 : 837 842, 2006
33. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 (4 Suppl. 3 S192 S240, 1997
34. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 14 (Suppl. 5 1 50, 1999
35. Jenkins K : A review of the updated European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. EDTNA ERCA J 31 : 156 159, 2005
36. Statement of John K. Jenkins, M.D. Director, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, before the Committee on Ways and Means, Subcommittee on Health, U.S. House of Representatives, June 26, 2007. Available at http://www.fda.gov/ola/2007/ esa062607.html
37. Strippoli GF, Craig JC, Manno C, Schena FP : Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15 : 3154 3165, 2004
38. National Guidelines Clearing House/Glossary. Available at http://www.guideline.gov/resources/glossary.asp x. Accessed July 17, 2007.
39. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR DRIVE Study Group : Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 8 : 975 984, 2007
40. Singh AK : The FDA black box for EPO: what should nephrologists do? Nephrol News Issues 21 : 55 56, 2007
41. Fishbane S, Berns JS : Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 : 1337 1343, 2005
42. Lacson E Jr., Ofsthun N, Lazarus JM : Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41 : 111 124, 2003
43. Berns JS, Elzein H, Lynn RI, Fishemoglobinane S, Meisels IS, Deoreo PB : Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64 : 1514 1521, 2003
44. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM : Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46 : 481 488, 2005